The company’s portfolio currently includes medicines that belong to the main therapeutic classes: cardiovascular system, central nervous system, anti-infectious, digestive system and a growing range of OTC drugs.
Actavis’ portfolio also includes over 25 cancer treatment drugs mainly produced at its plant in Bucharest.
End- 2012, Actavis was acquired by American group Watson Pharmaceuticals, which subsequently changed its name to Actavis. Watson paid EUR4.25 billion in cash for Actavis within a transaction that created the world’s third largest generic manufacturers, with revenue estimated at $8.1 billion in 2013.
Worldwide, Actavis owns over 30 production facilities, with an annual capacity of 44 billion units.
Actavis owns in Romania cancer drug maker Sindan acquired in 2006 for EUR150 million.